Artizan Biosciences is at the frontier of microbiome precision medicine, targeting, and blocking intestinal microbial-driven inflammation that are the root cause of many serious diseases.
Broad Approach
Using a novel small molecule approach, Artizan modulates intestinal dysbiosis by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract.
Discovery Platform
Artizan’s proprietary drug discovery engine identifies and characterizes microbial drivers of disease within precise patient subsets in high-value areas including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases.
News
-
November 18, 2021
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development program. (more…)
-
October 18, 2021
Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer
Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer. (more…)
Artizan’s world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls. These samples enable critical research into disease mechanisms and aid the development of potential treatments.